Mn Services Vermogensbeheer B.V. Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mn Services Vermogensbeheer B.V. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 198.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,063 shares of the pharmaceutical company’s stock after purchasing an additional 87,100 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Vertex Pharmaceuticals were worth $24,034,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Evolution Wealth Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $32,000. FTB Advisors Inc. increased its stake in shares of Vertex Pharmaceuticals by 1,618.2% during the 1st quarter. FTB Advisors Inc. now owns 189 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 178 shares during the last quarter. Pittenger & Anderson Inc. increased its stake in shares of Vertex Pharmaceuticals by 64.7% during the 1st quarter. Pittenger & Anderson Inc. now owns 191 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 75 shares during the last quarter. Thor Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $37,000. Finally, Pearl River Capital LLC acquired a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $44,000. Institutional investors own 95.02% of the company’s stock.

VRTX opened at $178.39 on Monday. The business’s 50 day simple moving average is $176.51. The firm has a market cap of $45.69 billion, a P/E ratio of 63.04, a PEG ratio of 2.58 and a beta of 1.41. Vertex Pharmaceuticals Incorporated has a 1 year low of $151.80 and a 1 year high of $195.81. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 2.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.24. The firm had revenue of $941.29 million during the quarter, compared to the consensus estimate of $884.66 million. Vertex Pharmaceuticals had a net margin of 64.13% and a return on equity of 21.73%. The company’s revenue was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.94 EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 3.07 EPS for the current year.

Vertex Pharmaceuticals announced that its Board of Directors has initiated a stock buyback plan on Wednesday, July 31st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the pharmaceutical company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 56,030 shares of the stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $175.39, for a total value of $9,827,101.70. Following the completion of the sale, the chief executive officer now owns 162,317 shares of the company’s stock, valued at $28,468,778.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Parini sold 2,125 shares of the stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $175.27, for a total transaction of $372,448.75. Following the completion of the sale, the executive vice president now directly owns 37,128 shares of the company’s stock, valued at approximately $6,507,424.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 179,145 shares of company stock valued at $31,406,110. Corporate insiders own 0.70% of the company’s stock.

A number of research analysts have recently commented on VRTX shares. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $212.00 price objective on shares of Vertex Pharmaceuticals in a research note on Thursday. Cowen set a $220.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 31st. Evercore ISI started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, April 11th. They set an “in-line” rating and a $183.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $220.00 price objective on shares of Vertex Pharmaceuticals in a research note on Thursday. Finally, Maxim Group reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $206.63.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Read More: What is the Fibonacci sequence?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.